Taken together, metallic nanomedicines hold significant promise in enhancing antitumor immune responses, either by directly activating innate immune pathways such as cGAS–STING or by potentiating PTT or RT-induced tumor ablation and subsequent ICD effects. The gene discussed is STING1; the disease is neoplasm.